Sequenom sex determination test
This article was originally published in The Gray Sheet
Executive SummarySequenom has launched its CLIA-laboratory-developed SensiGene Fetal (XY) fetal sex determination test, providing physicians with "accurate and noninvasive" fetal testing, firm announces Feb. 16. The test, which relies on a blood sample taken in a doctor's office and is performed on Sequenom's MassARRAY system, has a turnaround time of about one week. It showed a sensitivity of 97.9% and a specificity of 100% in a blinded study with over 200 samples evaluated at the Albert Einstein Medical Center in Philadelphia
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.